Compare · BDTX vs MRNA
BDTX vs MRNA
Side-by-side comparison of Black Diamond Therapeutics Inc. (BDTX) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDTX and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $20.47B, about 170.9x BDTX ($119.8M).
- Over the past year, BDTX is down 15.9% and MRNA is up 97.7% - MRNA leads by 113.6 points.
- MRNA has been more active in the news (16 items in the past 4 weeks vs 4 for BDTX).
- MRNA has more recent analyst coverage (25 ratings vs 13 for BDTX).
- Company
- Black Diamond Therapeutics Inc.
- Moderna Inc.
- Price
- $2.09-0.48%
- $51.60+5.22%
- Market cap
- $119.8M
- $20.47B
- 1M return
- -26.92%
- +10.46%
- 1Y return
- -15.90%
- +97.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 4
- 16
- Recent ratings
- 13
- 25
Black Diamond Therapeutics Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BDTX
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
- Black Diamond Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
- Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
- Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Black Diamond Therapeutics Inc.
- Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Black Diamond Therapeutics Inc.
- SEC Form DEF 14A filed by Black Diamond Therapeutics Inc.
- Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Latest MRNA
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)
- President Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)
- Director Afeyan Noubar exercised 9,263 shares at a strike of $19.15 and sold $433,879 worth of shares (9,263 units at $46.84) (SEC Form 4)